119 related articles for article (PubMed ID: 6321686)
1. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.
Lippman ME; Cassidy J; Wesley M; Young RC
J Clin Oncol; 1984 Jan; 2(1):28-36. PubMed ID: 6321686
[TBL] [Abstract][Full Text] [Related]
2. Increasing the response rate to cytotoxic chemotherapy by endocrine means.
Lippman ME; Cassidy J; Wesley M; Young RC
J Steroid Biochem; 1985 Dec; 23(6B):1173-80. PubMed ID: 3005774
[TBL] [Abstract][Full Text] [Related]
3. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
Lippman ME; Sorace RA; Bagley CS; Danforth DW; Lichter A; Wesley MN
NCI Monogr; 1986; (1):153-9. PubMed ID: 3022156
[TBL] [Abstract][Full Text] [Related]
4. Cytoxan, epirubicin, methotrexate and 5-fluorouracil with hormonal synchronization (tamoxifen/premarin) in advanced breast cancer. Preliminary results.
Zaniboni A; Simoncini E; Marpicati P; Gorni F; Cervi GC; Marini G
Chemioterapia; 1986 Oct; 5(5):341-6. PubMed ID: 3024851
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
Allegra JC
Semin Oncol; 1983 Jun; 10(2 Suppl 2):23-8. PubMed ID: 6306835
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
[TBL] [Abstract][Full Text] [Related]
7. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.
Eisenhauer EA; Bowman DM; Pritchard KI; Paterson AH; Ragaz J; Plenderleith I; Geggie PH; Maxwell I
Cancer Treat Rep; 1984 Nov; 68(11):1421-2. PubMed ID: 6094005
[No Abstract] [Full Text] [Related]
9. Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: results of a prospective randomized study.
Fukutomi T; Akashi S; Nanasawa T; Yamamoto H
J Surg Oncol; 1995 Dec; 60(4):242-6. PubMed ID: 8551733
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
Viladiu P; Alonso MC; Avella A; Beltrán M; Borrás J; Ojeda B; Bosch FX
Cancer; 1985 Dec; 56(12):2745-50. PubMed ID: 3902200
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
[TBL] [Abstract][Full Text] [Related]
13. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
15. UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain.
Iglesias L; Moreno JA; Torrija E; Murillo E; Codes M; Dugue A; Garcia E; Virizuela JA
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):74-81. PubMed ID: 9348574
[TBL] [Abstract][Full Text] [Related]
16. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
19. [Metastatic breast cancer: controlled trial of chemotherapy with and without hormones].
Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Magdelenat H; Asselain B; Pouillart P
Bull Cancer; 1984; 71(5):432-41. PubMed ID: 6395920
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
